JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy.

ABSTRACT:

Background

JAK1 is a signaling molecule downstream of cytokine receptors, including IL-4 receptor α. Abrocitinib is an oral JAK1 inhibitor; it is a safe and effective US Food and Drug Administration-approved treatment for adults with moderate-to-severe atopic dermatitis.

Objective

Our objective was to investigate the effect of abrocitinib on basophil activation and T-cell activation in patients with peanut allergy to determine the potential for use of JAK1 inhibitors as a monotherapy or an adjuvant to peanut oral immunotherapy.

Methods

Basophil activation in whole blood was measured by detection of CD63 expression using flow cytometry. Activation of CD4⁺ effector and regulatory T cells was determined by the upregulation of CD154 and CD137, respectively, on

SUBMITTER: Ramsey N 

PROVIDER: S-EPMC10501208 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature